A Cisplatin Derivative Tetra-Pt(bpy) as an Oncotherapeutic Agent for Targeting ALT Cancer.
Background: In approximately 15% of human cancers, telomere length is maintained independently of telomerase by the homologous recombination (HR)-mediated alternative lengthening of telomeres (ALT) pathway. Whether the ALT pathway can be exploited for therapeutic treatment remains unknown. The purpo...
| Published in: | JNCI: Journal of the National Cancer Institute Vol. 109; no. 10; pp. 1 - 12 |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| Format: | pictorial research tables/charts Journal Article |
| Published: |
Oxford University Press / USA
Oct2017
|
| Online Access: | View this record in EBSCOhost |